| June 5, 2014 | ISSUE NUMBER 354 VOL 4 |
|
R&D
The Graying of Clinical Trials — Why the Age Limit Should be Extended to 75
Patients 65 years of age and over are underrepresented in clinical trials, even though in many therapeutic categories they are the primary drug consumers. But, writes Sydney Rubin, there are few practical or ethical obstacles to including elderly patients in trials that cannot be overcome ...Read more
Digital Marketing
Lack of Multichannel Confidence is a Step on the Road to Digital Maturity
It would be easy to see this year’s Across Health Multichannel Barometer survey results as further evidence that pharma is doomed to never get digital. But, writes Peter Houston, there is optimism that the results are a sign of the industry’s digital maturity
...Read more
Regulatory
Things Look Up for Obamacare, but New HHS Chief Faces Tough 2015
The Obama administration received a lot of good news last month. Eight million enrolled in qualified health plans and millions more joined Medicaid. Health and Human Services (HHS) Secretary Kathleen Sebelius was able exit her post in a good light. But, writes Jill Wechsler, her successor faces a multitude of challenges
...Read more
Global
India’s Renewed Pharma Market Potential
Recent changes in India’s population and economy have contributed to a shift in the country’s epidemiological profile towards ‘lifestyle’ diseases that are more prevalent in Western markets. Such changes have increased the demand for better healthcare and for medications that address chronic diseases ...Read more
A solid health care investment. 50+% gross margins on products and services in which patients pay 100%? Consumers today have strong financial incentives to stay healthy to reduce their reliance on expensive treatment. MMSN is a retailer of natural nutrition products & counseling services with a proven 24-year track record, strong financial performance, and 150+ franchised locations. They are expanding with qualified investors. Read more
Finance
Rise in IPOs Eases Pharma’s Investment Pain
Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, with the pharma, biotech and healthcare equipment sectors the sharpest declines, says a new report. But there is a silver lining to this gloomy news ...Read more
New Report
Product Cycle Strategies for Greater Profitability
In this compilation of four in-depth, data-rich reports from Pharmaceutical Executive, you'll learn a new set of metrics allowing companies to align their strategies around the push for greater profitability, putting them on the right track ...Read more |
|
|
|
 //Auxilium Pharmaceuticals, Inc. (Chesterbrook, PA) announced that its Chief Financial Offier, James E. Fickenscher, is leaving the company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15.//Curis, Inc. (Lexington, MA) named Ali Fattaey, Ph.D, as President and CEO. Daniel Passeri assumes the role of Strategic Director and Vice Chairman, Curis Board of Directors.//Zosano Pharma, Inc. (Fremont, CA) announced the appointment of Winnie W. Tso, CPA, as Chief Financial Officer.//Kite Pharma, Inc. (Santa Monica, CA) named David D. Chang, M.D., Ph.D., as Executive Vice President, Research and Development, and Chief Medical Officer.// |
|
|
|
|
|
 |
|
|
| |
|
 |
|
 |
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
|
|
|
|
